Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 8/20 | 0.67 |
| ▸ | LPL | P06858 | 4/20 | 0.65 |
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MGLL | Q99685 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3132606 | 0.91 | ENPP2 (0.56) | ENPP2LPLLIPGKDM4EALDH1A1 | |
| SCHEMBL2575334 | 0.87 | LPL (0.57) | ENPP2LPLLIPGKDM4EALDH1A1 | |
| SCHEMBL7404148 | 0.86 | LPL (0.64) | ENPP2LPLLIPGKDM4EALDH1A1 | |
| SCHEMBL2555516 | 0.83 | ENPP2 (0.59) | ENPP2LPLLIPGKDM4EALDH1A1 | |
| SCHEMBL1421621 | 0.83 | LPL (0.77) | ENPP2LPLLIPGKDM4EALDH1A1 | |
| SCHEMBL10136926 | 0.82 | LPL (0.69) | ENPP2LPLLIPGKDM4EALDH1A1 | |
| SCHEMBL5872608 | 0.82 | ENPP2 (0.72) | ENPP2LPLLIPGKDM4EALDH1A1 | |
| SCHEMBL12266159 | 0.82 | TRPV6 (0.54) | ENPP2LPLLIPGALDH1A1TP53 | |
| SCHEMBL3138179 | 0.80 | LPL (0.90) | ENPP2LPLLIPGMGLL | |
| SCHEMBL22960607 | 0.80 | LPL (0.45) | ENPP2LPLLIPGKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 304 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115928264-A | Preparation method of metal-containing near-stoichiometric continuous silicon carbide fiber | 湖南泽睿新材料有限公司 | 2023-04-07 | — | — | CN | claimed |
| US-20260001871-A1 | TRIAZOLE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR D | ESCIENT PHARMACEUTICALS INC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4644388-A1 | FIVE-MEMBERED HETEROARYL COMPOUND AND AGRICULTURAL AND HORTICULTURAL BACTERICIDE | Nippon Soda Co., Ltd. (JP) | 2025-11-05 | — | — | EP | disclosed |
| US-12378224-B2 | Heteroaryl compounds and their use as Mer inhibitors | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2025-08-05 | — | — | US | disclosed |
| EP-4559918-A2 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Genzyme Corporation (US) | 2025-05-28 | — | — | EP | disclosed |
| EP-3673906-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORP (US) | 2025-05-14 | — | — | EP | disclosed |
| EP-4543543-A1 | TRIAZOLE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR D | ESCIENT PHARMACEUTICALS, INC. (US) | 2025-04-30 | — | — | EP | disclosed |
| US-20250127907-A1 | PARP INHIBITORS | Stablix, Inc. | 2025-04-24 | — | — | US | disclosed |
| US-12195447-B2 | Azolopyrimidine for the treatment of cancer-related disorders | ARCUS BIOSCIENCES, INC. (US) | 2025-01-14 | — | — | US | disclosed |
| CN-115806501-B | N-oxalyl-D-phenylalanine compounds and ester prodrugs thereof, preparation method, pharmaceutical composition and application | 中国药科大学 | 2025-01-07 | — | — | CN | disclosed |
| US-6495568-B1 | TREATMENT OF TISSUE ULCERATION, WOUND REPAIR AND SKIN DISEASES | WARNER-LAMBERT COMPANY | 2002-12-17 | — | — | US | disclosed |
| EP-0675118-B1 | Biphenylderivatives, process for their preparation and their use as medicaments | EISAI CO LTD (JP) | 2002-10-09 | — | — | EP | disclosed |
| US-6281214-B1 | USEFUL FOR TREATING AND AMELIORATING MENTAL DISORDERS | EISAI CO., LTD (JP) | 2001-08-28 | — | — | US | disclosed |
| US-6265606-B1 | TO CONTROL A BROAD SPECTRUM OF UNDESIRABLE VEGETATION, ARE SELECTIVE TO MAJOR CROPS, HAVE DESIRABLE ENVIRONMENTAL PROFILES, | DOW AGROSCIENCES LLC | 2001-07-24 | — | — | US | disclosed |
| CN-1290700-A | Phenyl piperazine derivatives | EISAI LTD (JP) | 2001-04-11 | — | — | CN | disclosed |
| US-6010981-A | 1-alkyl-4-benzoyl-5-hydroxypyrazole compounds and their use as herbicides | DOW AGROSCIENCES LLC (US) | 2000-01-04 | — | — | US | disclosed |
| EP-0914317-A2 | 1-ALKYL-4-BENZOYL-5-HYDROXYPYRAZOLE COMPOUNDS AND THEIR USE AS HERBICIDES | Dow AgroSciences LLC (US) | 1999-05-12 | — | — | EP | disclosed |
| WO-1998052926-A2 | 1-ALKYL-4-BENZOYL-5-HYDROXYPYRAZOLE COMPOUNDS AND THEIR USE AS HERBICIDES | DOW AGROSCIENCES LLC (US) | 1998-11-26 | — | — | WO | disclosed |
| CN-1117966-A | Biphenyl derivatives | EISAI CO LTD (JP) | 1996-03-06 | — | — | CN | disclosed |
| EP-0675118-A2 | Biphenylderivatives, process for their preparation and their use as medicaments | Eisai Co., Ltd. (JP) | 1995-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12378224-B2 | Heteroaryl compounds and their use as Mer inhibitors | MERTK, RET, ERBB2 | ENPP2 2205/4885LPL 2371/4885LIPG 1264/4885 |
| US-12195447-B2 | Azolopyrimidine for the treatment of cancer-related disorders | ADORA2A, ADORA2B, ADORA1 | ENPP2 48/4885LPL 4267/4885LIPG 4042/4885 |
| US-20260001871-A1 | TRIAZOLE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR D | MRGPRX2, MC2R, MRGPRX1 | ENPP2 1139/4885LPL 2008/4885LIPG 2466/4885 |
| US-20250127907-A1 | PARP INHIBITORS | PARP1, PARP2, PARP3 | ENPP2 1114/4885LPL 4170/4885LIPG 3286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.